Can a blue dye tame Immunotherapy's dangerous side effects?
NCT ID NCT07169487
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests whether methylene blue, a dye used in medicine for other conditions, can safely treat two serious side effects of certain cancer immunotherapies: cytokine release syndrome (CRS) and immune-related neurotoxicity (ICANS). The study will enroll 18 adults with blood cancers who develop these side effects after CAR-T or bispecific antibody treatment. Participants receive methylene blue infusions for 3-5 days at different doses to find the safest and most promising dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
methylene blue
What this could lead to
If it works, this could offer a new way to manage serious side effects of cancer immunotherapy, potentially making treatment safer and more tolerable.
What could go wrong
This is a very early Phase 1 trial with only 18 people, so it is too soon to know if methylene blue is safe or effective. The results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact